Anti-TNF-alpha antibodies and their uses
AssigneeAbbVie Biotherapeutics Inc.
InventorsFiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α.
Claims36
A method of treating an immune disorder selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis, comprising administering to a human patient in need thereof a therapeutically effective amount of an anti-TNF-α antibody or anti-TNF-α binding fragment thereof which:
- (a) specifically binds to human TNF-α;
- and
- (b) comprises a heavy chain amino acid sequence having at least 95% sequence identity to SEQ ID NO:2 and a light chain amino acid sequence having at least 95% sequence identity to SEQ ID NO:4,
- wherein the heavy and light chain amino acid sequences comprise one or more amino acid substitutions or combinations of amino acid substitutions selected from:
- (1) the CDR-L1 substitutions R7Q;
- A11S;
- R7Q+A11S;
- N8T;
- N8T+A11S;
- I6T;
- A11G;
- I6T+A11G;
- Q4G;
- Q4G+A11S;
- Q4G+A11G;
- Q4H;
- Q4H+A11S;
- Q4R+A11S;
- G5S+A11S;
- N8S+A11S;
- I6T+A11S;
- and N8T+A11G;
- (2) the CDR-L2 substitutions S3K or S3R;
- T4H, T4Q, T4F, T4W or T4Y;
- L5R or L5K;
- and Q6R;
- (3) the CDR-H1 substitutions:
- Y2H and A3G;
- and
- (4) the CDR-H2 substitution:
- T3N,
- wherein the numbering of the amino acids corresponds to the positions in the CDRs of D2E7.
Dependencies are inferred from the claim text.